Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

A Study of the Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination with Venetoclax in AML Ended

2024-516294-78-00 Acute Myeloid Leukemia (AML) 2022-06-17
A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects wi… Ended

2024-513177-48-00 Chronic Hepatitis B Virus Infection 2022-06-16
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cho… Ended

2023-505764-11-00 Pruritus associated with Primary Sclerosing Cholangitis 2022-06-10
SEQUEL-Breast: a phase 2 study on the combination of alpelisib and fulvestrant after progression on previous therapy with fulvestrant in pat… Ended

2024-514965-20-00 Breast cancer 2022-06-02
A multicentre phase II, single arm study of Durvalumab (MEDI 4736) with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maint… Ended

2024-516157-41-00 Metastatic pulmonary large-cell neuroendocrine carcinom 2022-05-27
A research study to evaluate the activity of Sotorasib for the treatment of patients with non-operable non-small cell lung cancer with a KRA… Ended

2024-511268-10-00 Unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12 2022-05-25
IFCT-2101 MASTERPROTOCOL ALK : Study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monot… Ended

2023-510387-13-00 advanced ALK-positive non-small cell lung cancer 2022-05-18
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myel… Ended

2023-507469-24-00 Anemia in Patients with Very Low, Low, or Intermediate 2022-04-30
Daratumumab in ME/CFS Ended

2024-512500-19-00 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 2022-04-29
A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis Ended

2023-507069-25-00 Amyloid Light Chain Amyloidosis 2022-04-29
To evaluate the efficacy and safety of regorafenib in patients with refractory primary bone tumors. Ended

2024-514720-17-00 Refractory primary bone tumors 2022-04-29
New Clinical End-points in patients with primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients Ended

2023-510054-16-00 Primary Sjogren's syndrome 2022-04-26
DISCUS: A Randomised Phase II Study Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothel… Ended

2024-518244-20-01 Urothelial Carcinoma 2022-04-25
A study to evaluate KER-050 as a monotherapy or in combination with Ruxolitinib in Myelofibrosis. Ended

2023-507468-38-00 Myelofibrosis 2022-04-22
Morphine effects on stress response and social interaction – an exploratory randomized controlled experimental medicine study Ended

2024-517855-10-00 Healthy volunteers 2022-04-20
A Phase 2 study of INBRX-109 in adults with a type of unresectable or metastasized cancer of the bones and joints (Conventional Chondrosarco… Ended

2024-517528-20-00 Unresectable or metastatic conventional chondrosarcoma 2022-04-19
A Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non−Small-Cell Lung Ca… Ended

2024-513225-23-00 Non-small cell lung cancer 2022-04-07
Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer. POINT study Ended

2024-511901-52-00 Adult patients affected by recurrent/metastatic, platin 2022-03-24
A Phase II, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Canakinumab for the Treatment of Anemia in Patients with IPSS-… Ended

2024-515886-33-00 Lower-risk MDS or MDS/MPN 2022-03-23
Consolidation with ADCT-402 (loncastuximab tesirine) after a short course of immunochemotherapy: a phase II study in BTKi-treated (or BTKi i… Ended

2024-511633-35-00 Mantle cell lymphoma 2022-03-21
Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 Ended

2024-516293-29-01 Acute myeloid lymphoma (AML), myelodysplastic syndrome 2022-03-17
TORNADO : RANDOMIZED PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY PLUS RETIFANLIMAB (INCMGA00012) IN PATIENTS WITH SELECTED RETROPERITONEAL SA… Ended

2023-509498-21-00 Adult patients with treatment-naïve surgically non-meta 2022-03-16
Efficacy and safety of Frexalimab (SAR441344) in the treatment of Systemic Lupus Erythematosus Ended

2023-508654-26-00 Systemic lupus erythematosus 2022-03-15
Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to evaluate the efficacy and safety of the combination regimen Isatuxima… Ended

2024-512749-18-00 Newly diagnosed Multiple Myeloma 2022-03-03